

The Future of IMI

- The Second Wave of Projects
- The Third Call for Proposals
- The Revision of the Strategic Research Agenda
- The Intellectual Property Policy



Agenda



Innovative Medicines Initiative

- **The 3rd Call for proposals (2010)**

Titta Rosvall-Puplett, Director Research Directors Group, EFPIA

- **Towards a new Research Agenda**

Christian Noë, chair of the Scientific Committee

- **Q&A**

10:45 – 11:15 Coffee break

- **New ways of sharing knowledge**

Magali Poinot, Legal Manager IMI

- **Round table Q&A**

Lessons from Ongoing Projects



- **First successes and enthusiasm** within 1st Call projects provide « **proof-of-concept** » evidence for IMI-type PPPs
- **IMI is more than a industry-academia PPP**: successful involvement of regulatory agencies, patients' organizations and SMEs
- **Boundaries of pre-competitive research and IP rules** are more difficult to define in « Efficacy » projects
- Need for dedicated tools for **data and knowledge management**



To be Kept in Mind....



IMI is a **European Public-Private** partnership

focused on **unmet needs** common to

pharmaceutical industry and **patients**



Annual Stakeholder Forum, 14-15 June 2010



efpia

SRA Revision: Tentative Timelines



- Feb-June 2010: Elaboration of « Status Report » by SC
- 1-2 June 2010: Preparatory workshops
- 15 June 2010: Stakeholders forum
- July-Sept 2010: Launch of electronic consultation on key questions
- Sept-Nov 2010: Preparation of first draft
- Dec 2010: Draft finalization
- Dec 2010-Jan 2011: Approval by Governing Board



The IMI Research Agenda



- Based on the agenda developed by the European Technology Platform on Innovative Medicines to address bottlenecks in drug development in the European Union
- Elaborated between October 2004 and March 2008
- Conceived as a « living document » to be updated upon consultation of stakeholders
- The IMI Scientific Committee advises on the relevance of the agenda and recommends amendments

